Higher local Ebola incidence causes lower child vaccination rates

The impact of the Ebola epidemic on the child vaccination rate.

Resmetirom Poised to Become First NASH Treatment

Groundbreaking results from a phase III trial have set the stage for resmetirom to become the first drug approved for patients with nonalcoholic steatohepatitis (NASH)

February 8, 2024

Heated lawsuit between AdventHealth, MultiPlan attracts hospital lobbyists

A lawsuit between a large hospital system and a dominant vendor that works for health insurance companies is getting a lot more heated — with

January 10, 2024

Gilead’s twice-a-year injection fully prevented HIV in Phase 3 study with cisgender women

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 21, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.